Recursion Pharmaceuticals, Inc. (RXRX) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
Recursion Pharmaceuticals, Inc. (RXRX) Profile & Business Summary
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Key Information
| Ticker | RXRX |
|---|---|
| Leadership | Najat Khan |
| Exchange | NASDAQ |
| Official Site | https://www.recursion.com |
Market Trend Overview for RXRX
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
This model looks at how prices behave over time to describe the current market environment. It focuses on whether price is moving steadily, stalling, or losing momentum, and checks both short-term and weekly trends for confirmation. The goal is not to predict exact prices, but to help understand when conditions are supportive, risky, or unclear.
Current Market Context (Short-Term)
As of 2026-02-06 (ET), RXRX has no clear direction right now. Price at 3.98 is close to support near 3.81. Moves may slow down, and resistance is near 4.37. View Support & Resistance from Options
Why the market looks this way?
Recent price signals are mixed and do not point clearly in one direction. This makes the current environment harder to read until a clearer move appears.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-02-06 (ET)
As of 2026-02-06, RXRX is showing signs of slowing down. Over the longer term, the trend remains bearish.
RXRX last closed at 3.98. The price is about 0.2 ATR below its recent average price (4.04), and the market is currently in a trend that may be losing strength.
Short-term and long-term trends are aligned to the downside, keeping downside risk dominant.
Trend score: 45 out of 100. Overall alignment is unclear. The market is currently in a late-stage trend that may be losing strength. The longer-term trend is still negative, but short-term signals are not yet confirming it.
There is no clear risk level acting as a key boundary right now.
On 2026-01-22, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-01-28] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
Some late-day positioning was observed, but it lacked strong overnight commitment.
Short Interest & Covering Risk for RXRX
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is relatively low, indicating limited pressure from short positions. (Historical percentile: 19%)
Structure Analysis
RXRX Short positioning is starting to look crowded. Current days to cover is 8.2 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves.
Bull Trap Structural Risk
Risk conditions are elevated. Recent price strength may be less stable if selling pressure increases.This indicator is intended as a risk filter, not a directional signal. A High or Extreme reading does not predict an immediate move, but suggests that if prices weaken, downside reactions may be more pronounced.
Elevated short crowding (short interest as a share of float is above normal). Average trading volume is weakening, indicating contracting liquidity. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-01-15 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.